Phaseline

Targets › TFRC

TFRC (Transferrin receptor protein 1): drug programs, companies and trials

2 programs from 2 companies in 4 trials: 3 Phase 2, 1 Phase 3; Metabolic and endocrine, Hematology; next expected readout Dec 2026.

Cellular uptake of iron occurs via receptor-mediated endocytosis of ligand-occupied transferrin receptor into specialized endosomes. Endosomal acidification leads to iron release. (UniProt, P02786)

Open in Phaseline: the race on TFRC, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
JCR PharmaceuticalsPabinafusp Alfa (JR-141)
Transferrin receptor binding agent
TFRC, TFR2Phase 3Mucopolysaccharidosis IIDec 2026
Halia TherapeuticsHT-6184
CD71 transferrin receptor antagonist
TFRCPhase 2Myelodysplastic Syndrome–

Conditions

Mucopolysaccharidosis II (3) Myelodysplastic Syndrome (1)

Modalities

small molecule (2)

Companies

JCR Pharmaceuticals (1) Halia Therapeutics (1)

Related targets

TFR2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.